Diagnostic Value of Anti‐F‐Actin Antibodies in a French Multicenter Study

Chretien-Leprince, P; Ballot, Éric; André, C.; Olsson, Nils‐Olivier; Fabien, Nicole; Escande, Aurélie; Oksman, F; Dubuquoi, S; Jego, Sonia; Goetz, Joëlle; Chevailler, Alain; Sanmarco, Marielle; Humbel, René‐Louis; Johanet, Catherine

doi:10.1196/annals.1313.028

Cited by 39 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antibodies to F-actin can also be found in patients with viral hepatitis, but usually they are present in lower levels than those seen in AIH-1 (14,15). The present study is in agreement with these observations, as we found 25% of patient sera having serologies consistent with viral hepatitis were positive for F-actin IgG with the majority (59.3%) of these sera having low levels (Table 3).…”

Section: Discussionsupporting

confidence: 95%

Prevalence of IgG autoantibody against F‐actin in patients suspected of having autoimmune or acute viral hepatitis

Jaskowski

Konnick

Ashwood

et al. 2007

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Our objectives in this study were to compare results obtained by an enzyme immunoassay (EIA) for F-actin antibody (FAA) immunoglobulin G (IgG) to those determined by an indirect fluorescent antibody (IFA) assay for smooth muscle antibody (SMA) IgG, and to determine the prevalence of FAA in patient sera having serologic evidence of acute viral hepatitis. Sera from 415 patients suspected of having autoimmune hepatitis (AIH), 208 patients suspected of having acute viral hepatitis A, B, or C, and 100 healthy blood donors (HBD) were included in the study. Only one of 100 HBD showed low levels (20-30 Units) of F-actin IgG. In patients suspected of having AIH, the prevalence of FAA increased as SMA titers increased and all sera with SMA titers of >or=1:160 were FAA-positive. In contrast, there were many sera with negative (<1:20) or low (1:20-1:40) SMA titers that contained moderate to high levels (>30 Units) of FAA; many exceeding 80 Units. Moreover, 51.4% of these sera were also positive for anti-nuclear antibody (ANA), which is also utilized in diagnosing type 1 AIH. FAA was detected in 25% of viral hepatitis antibody-positive sera, with the majority (59.3%) containing low levels, and all were ANA-negative.

show abstract

Section: Discussionsupporting

confidence: 95%

Prevalence of IgG autoantibody against F‐actin in patients suspected of having autoimmune or acute viral hepatitis

Jaskowski

Konnick

Ashwood

et al. 2007

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…Although the presence of anti-actin antibodies in patients with chronic hepatitis C infection was previously described (11)(12)(13)(14), the prevalence of either ASMA or anti-actin positivity was particularly high in our study. Out of the 33 HCV samples, 19 (57%) were ASMA positive, 7 (21%) were anti-actin positive and 6 (18%) of them both ASMA and anti-actin positive.…”

Section: Discussioncontrasting

confidence: 72%

Improved diagnoses of autoimmune hepatitis using an anti‐actin ELISA

Aubert

Pisler

Spertini

2008

Clinical Laboratory Analysis

View full text Add to dashboard Cite

The presence of antismooth muscle antibodies is one of the diagnostic criteria of autoimmune hepatitis. We evaluated a new anti-F-actin ELISA test and compared it with indirect immunofluorescence assay (IIFA) for antismooth muscle antibodies (ASMA). Two hundred and nine serum samples (35 autoimmune hepatitis, 174 other hepatopathies and control sera) were tested by IIFA on mouse stomach kidney sections for ASMA and by the Quanta Lite Actin ELISA for anti-F-actin antibodies. ASMA were detected in 26 of 35 sera from autoimmune hepatitis (74%) as compared with 25 (71%) with anti-actin antibodies, as well as in 25 of 49 (51%) samples from viral hepatitis as compared with 7 (14%) with anti-actin antibodies. With regards to autoimmune hepatitis, though sensitivity (74.3 vs 71.4%) and negative predictive value (93.5 vs 93.9%) of ASMA and anti-actin ELISA were comparable, anti-actin ELISA was significantly better than ASMA IIFA in terms of specificity (89.7 vs 74.7%), and positive predictive value (58.1 vs 37.1%). Although frequently positive in HCV samples, a comparable sensitivity but better specificity makes the anti-actin ELISA a useful tool in combination with ASMA IIFA for the screening and diagnosis of autoimmune hepatitis.

show abstract

“…Antibodies to actin can be demonstrated by indirect immunofluorescence of microfilaments in HEp-2 cells or fibroblasts treated with vinblastine or colchicine [65,66]. They can also be detected by indirect immunofluorescence of liver sections from rats chronically injected with phalloidin [65] or by assessing peritubular and glomerular structures in rat kidney [67].…”

Section: Antibodies To Actinmentioning

confidence: 97%

Autoantibodies as Prognostic Markers in Autoimmune Liver Disease

Czaja

2010

Dig Dis Sci

View full text Add to dashboard Cite

Certain autoantibodies in autoimmune liver disease have prognostic implications that are under-utilized and under-developed. The goals of this review are to indicate progress in characterizing the autoantibodies with prognostic connotations and to indicate the feasibility and importance of discovering other markers. Prime source and review articles in English were selected by a Medline search through 2010. Antibodies to soluble liver antigen, actin, liver cytosol type 1, asialoglycoprotein receptor, chromatin, cyclic citrullinated peptide, and uridine glucuronosyltransferases have been associated with the occurrence, severity, and progression of autoimmune hepatitis, and antibodies to Sp100, gp210, and centromere have had similar implications in primary biliary cirrhosis. Antibodies to soluble liver antigen have shown the most promise in autoimmune hepatitis as they have been associated with severe histological changes, long durations of treatment, relapse after drug withdrawal, and high frequency of liver failure. Antibodies to the nuclear rim pore protein, gp210, have shown the most promise in primary biliary cirrhosis as they have been associated with severe interface hepatitis, lobular inflammation, and progression to liver failure. The major limitations of the autoantibodies have been their lack of standardized assays, low negative predictabilities, and fluctuating levels. Performance parameters will improve as critical pathogenic pathways, comprehensive testing batteries, and standardized assays through international exchange workshops are developed. Progress has been made in identifying the serological markers of prognosis in autoimmune liver disease, and they promise to reflect critical disease mechanisms and enhance patient management.

show abstract

Diagnostic Value of Anti‐F‐Actin Antibodies in a French Multicenter Study

Cited by 39 publications

References 23 publications

Prevalence of IgG autoantibody against F‐actin in patients suspected of having autoimmune or acute viral hepatitis

Prevalence of IgG autoantibody against F‐actin in patients suspected of having autoimmune or acute viral hepatitis

Improved diagnoses of autoimmune hepatitis using an anti‐actin ELISA

Autoantibodies as Prognostic Markers in Autoimmune Liver Disease

Contact Info

Product

Resources

About